European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism
C Pristipino, H Sievert, F D'ascenzo… - European Heart …, 2019 - academic.oup.com
The presence of a patent foramen ovale (PFO) is implicated in the pathogenesis of a number
of medical conditions; however, the subject remains controversial and no official statements …
of medical conditions; however, the subject remains controversial and no official statements …
Cryptogenic stroke
JL Saver - New England Journal of Medicine, 2016 - Mass Medical Soc
Key Clinical Points Cryptogenic Stroke One quarter of patients with ischemic stroke have no
probable cause found after standard workup, including echocardiography, inpatient cardiac …
probable cause found after standard workup, including echocardiography, inpatient cardiac …
Heterogeneity of treatment effects in an analysis of pooled individual patient data from randomized trials of device closure of patent foramen ovale after stroke
Importance Patent foramen ovale (PFO)–associated strokes comprise approximately 10% of
ischemic strokes in adults aged 18 to 60 years. While device closure decreases stroke …
ischemic strokes in adults aged 18 to 60 years. While device closure decreases stroke …
[HTML][HTML] Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke
JL Mas, G Derumeaux, B Guillon… - … England Journal of …, 2017 - Mass Medical Soc
Background Trials of patent foramen ovale (PFO) closure to prevent recurrent stroke have
been inconclusive. We investigated whether patients with cryptogenic stroke and …
been inconclusive. We investigated whether patients with cryptogenic stroke and …
Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke
L Søndergaard, SE Kasner, JF Rhodes… - … England Journal of …, 2017 - Mass Medical Soc
Background The efficacy of closure of a patent foramen ovale (PFO) in the prevention of
recurrent stroke after cryptogenic stroke is uncertain. We investigated the effect of PFO …
recurrent stroke after cryptogenic stroke is uncertain. We investigated the effect of PFO …
Cryptogenic stroke and high-risk patent foramen ovale: the DEFENSE-PFO trial
Background: Recent reports showing the favorable role of patent foramen ovale (PFO)
closure in patients with cryptogenic stroke have raised the issue of selecting optimal …
closure in patients with cryptogenic stroke have raised the issue of selecting optimal …
Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association
JF Meschia, C Bushnell, B Boden-Albala, LT Braun… - Stroke, 2014 - Am Heart Assoc
The aim of this updated statement is to provide comprehensive and timely evidence-based
recommendations on the prevention of stroke among individuals who have not previously …
recommendations on the prevention of stroke among individuals who have not previously …
Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart …
WN Kernan, B Ovbiagele, HR Black, DM Bravata… - Stroke, 2014 - Am Heart Assoc
The aim of this updated guideline is to provide comprehensive and timely evidence-based
recommendations on the prevention of future stroke among survivors of ischemic stroke or …
recommendations on the prevention of future stroke among survivors of ischemic stroke or …
Embolic strokes of undetermined source: the case for a new clinical construct
Cryptogenic (of unknown cause) ischaemic strokes are now thought to comprise about 25%
of all ischaemic strokes. Advances in imaging techniques and improved understanding of …
of all ischaemic strokes. Advances in imaging techniques and improved understanding of …
Guidelines for performing a comprehensive transesophageal echocardiographic examination: recommendations from the American Society of Echocardiography and …
RT Hahn, T Abraham, MS Adams, CJ Bruce… - Journal of the American …, 2013 - Elsevier
Author links open overlay panel Rebecca T. Hahn MD, FASE, Chair a, Theodore Abraham
MD, FASE b, Mark S. Adams RDCS, FASE c, Charles J. Bruce MD, FASE d, Kathryn E. Glas …
MD, FASE b, Mark S. Adams RDCS, FASE c, Charles J. Bruce MD, FASE d, Kathryn E. Glas …